Article (Scientific journals)
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray, John J. V.; Packer, Milton; Desai, Akshay S. et al.
2014In The New England journal of medicine, 371 (11), p. 993-1004
Peer reviewed
 

Files


Full Text
nejmoa1409077.pdf
Publisher postprint (660.87 kB)
Download

All documents in ORBilu are protected by a user license.

Send to



Details



Keywords :
Aged; Aminobutyrates/adverse effects/therapeutic use; Angiotensin Receptor Antagonists/adverse effects/therapeutic use; Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use; Double-Blind Method; Drug Combinations; Enalapril/adverse effects/therapeutic use; Female; Heart Failure/drug therapy/mortality; Hospitalization/statistics & numerical data; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neprilysin/antagonists & inhibitors; Stroke Volume; Tetrazoles/adverse effects/therapeutic use
Abstract :
[en] BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
McMurray, John J. V.
Packer, Milton
Desai, Akshay S.
Gong, Jianjian
Lefkowitz, Martin P.
Rizkala, Adel R.
Rouleau, Jean L.
Shi, Victor C.
Solomon, Scott D.
Swedberg, Karl
Zile, Michael R.
Other collaborator :
Neyses, Ludwig ;  University of Luxembourg > Rectorate > Research Service
External co-authors :
yes
Language :
English
Title :
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
Publication date :
2014
Journal title :
The New England journal of medicine
ISSN :
0028-4793
eISSN :
1533-4406
Volume :
371
Issue :
11
Pages :
993-1004
Peer reviewed :
Peer reviewed
Available on ORBilu :
since 09 June 2016

Statistics


Number of views
806 (7 by Unilu)
Number of downloads
1721 (0 by Unilu)

Scopus citations®
 
4689
Scopus citations®
without self-citations
4374
WoS citations
 
4242

Bibliography


Similar publications



Contact ORBilu